Implication of Cerebral Dopamine-β Hydroxylase for Cardiovascular and Mood Regulation in Rats

10.4077/CJP.2013.BAB103

Shang-Tang Chang；Yia-Ping Liu；Chuen-Lin Huang；Pei-Ying Wang；Che-Se Tung

cardiovascular ； cerebral ； dopamine-β-hydroxylase ； mood

The Chinese Journal of Physiology

56卷4期（2013 / 08 / 31）

209 - 218

英文

The essentiality of the role of norepinephrine (NE) in the central nervous system has recently been reconsidered. NE exerts many effects and mediates a number of functions in living organisms. Dopamine-β-hydroxylase (DBH) is the crucial enzyme for NE and epinephrine biosynthesis. Removal of this enzyme causes deficient NE at sympathetic terminals characterized by orthostatic hypotension in humans. The hypothesis tested in this study was that NE deficiency in the central nervous system caused autonomic failure in cardiovascular regulation. The immunotoxin anti-DBH-saporin (DSAP) was used to examine the putative role of cerebral NE. Male Sprague-Dawley rats were injected, intracerebroventricularly (icv), with DSAP and cardiovascular reactivity, as well as behavioral variables in the openfield locomotion test (OLT), sucrose intake test (SIT) and forced swim test (FST), were monitored for changes. The results indicated that treatment with DSAP caused significant reductions in spontaneous blood pressure (BP) and heart rate (HR), and a decrease in the rearing position on the OLT, in the same group of rats. In addition, a significant increase in mobility with low concurrent immobility frequencies was observed on the FST. However, there was no variation on the SIT. In conclusion, a deficiency in the cerebral DBH might dysregulate the autonomic outflows and, thus, leads to lower BP and HR. However, there was no mood change such as despair or anhedonia observed in the experiments.

1. Liu, Y.P.,Wang, H.C.,Tseng, C.J.,Tang, H.S.,Yin, T.H.,Tung, C.S.(2005).Effects of amphetamine on schedule-induced polydipsia.Chinese J. Physiol.,48,176-186.
   連結：
2. Lu, C.C.,Tseng, C.J.,Tang, H.S.,Tung, C.S.(2004).Orthostatic intolerance: potential pathophysiology and therapy.Chinese J. Physiol.,47,101-109.
   連結：
3. Antelman, S.M.,Caggiula, A.R.(1977).Norepinephrine-dopamine interactions and behavior.Science,195,646-653.
4. Archer, T.,Mohammed, A.K.,Ross, S.B.,Soderberg, U.(1983).Tmaze learning, spontaneous activity and food intake recovery following systemic administration of the noradrenaline neurotoxin, DSP4.Pharmacol. Biochem. Behav.,19,121-130.
5. Bannister, R.,Oppenheimer, D.R.(1972).Degenerative diseases of the nervous system associated with autonomic failure.Brain,95,457-474.
6. Barone, F.C.,Wayner, M.J.,Scharoun, S.L.,Guevara-Aguilar, R.,Aguilar-Baturoni, H.U.(1981).Afferent connections to the lateral hypothalamus: a horseradish peroxidase study in the rat.Brain Res. Bull.,7,75-88.
7. Berridge, C.W.,Waterhouse, B.D.(2003).The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes.Brain Res. Rev.,42,33-84.
8. Biaggioni, I.(2007).The sympathetic nervous system and blood volume regulation: lessons from autonomic failure patients.Am. J. Med. Sci.,334,61-64.
9. Biaggioni, I.,Goldstein, D.S.,Atkinson, T.,Robertson, D.(1990).Dopamine-beta-hydroxylase deficiency in humans.Neurology,40,370-373.
10. Black, I.B.,Petito, C.K.(1976).Catecholamine enzymes in the degenerative neurological disease idiopathic orthostatic hypotension.Science,192,910-912.
11. Blier, P.,Briley, M.(2011).The noradrenergic symptom cluster: clinical expression and neuropharmacology.Neuropsychiatr. Dis. Treat.,7,15-20.
12. Carson, R.P.,Robertson, D.(2002).Genetic manipulation of noradrenergic neurons.J. Pharmacol. Exp. Ther.,301,410-417.
13. Chen, H.I.,Chai, C.Y.,Tung, C.S.,Chen, H.C.(1979).Modulation of the carotid baroreflex function during volume expansion.Am. J. Physiol.,237,H153-H158.
14. Coote, J.H.(2007).Landmarks in understanding the central nervous control of the cardiovascular system.Exp. Physiol.,92,3-18.
15. Cryan, J.F.,Dalvi, A.,Jin, S.H.,Hirsch, B.R.,Lucki, I.,Thomas, S.A.(2001).Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs.J. Pharmacol. Exp. Ther.,298,651-657.
16. Cryan, J.F.,Page, M.E.,Lucki, I.(2002).Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test.Eur. J. Pharmacol.,436,197-205.
17. Dahlstroem, A.,Fuxe, K.,Olson, L.,Ungerstedt, U.(1964).Ascending Systems of Catecholamine Neurons from the Lower Brain Stem.Acta Physiol. Scand.,62,485-486.
18. Dampney, R.A.,Horiuchi, J.,Tagawa, T.,Fontes, M.A.,Potts, P.D.,Polson, J.W.(2003).Medullary and supramedullary mechanisms regulating sympathetic vasomotor tone.Acta Physiol. Scand.,177,209-218.
19. Delfs, J.M.,Zhu, Y.,Druhan, J.P.,Aston-Jones, G.S.(1998).Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat.Brain Res.,806,127-140.
20. Delini-Stula, A.,Mogilnicka, E.,Hunn, C.,Dooley, D.J.(1984).Novelty-oriented behavior in the rat after selective damage of locus coeruleus projections by DSP-4, a new noradrenergic neurotoxin.Pharmacol. Biochem. Behav.,20,613-618.
21. Dhir, A.,Kulkarni, S.K.(2007).Involvement of dopamine (DA)/ serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.Brain Res. Bull.,74,58-65.
22. Dremencov, E.,Mansari, M.,Blier, P.(2009).Brain norepinephrine system as a target for antidepressant and mood stabilizing medications.Curr. Drug Targets,10,1061-1068.
23. Drugan, R.C.,Macomber, H.,Warner, T.A.(2010).Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants.Psychopharmacology (Berl),212,85-91.
24. Elam, M.,Svensson, T.H.,Thoren, P.(1985).Differentiated cardiovascular afferent regulation of locus coeruleus neurons and sympathetic nerves.Brain Res.,358,77-84.
25. Elam, M.,Svensson, T.H.,Thoren, P.(1986).Locus coeruleus neurons and sympathetic nerves: activation by cutaneous sensory afferents.Brain Res.,366,254-261.
26. Ellison, G.D.(1975).Behavior and the balance between norepinephrine and serotonin.Acta Neurobiol. Exp. (Wars),35,499-515.
27. Goldstein, D.S.(2006).Orthostatic hypotension as an early finding in Parkinson's disease.Clin. Auton. Res.,16,46-54.
28. Goldstein, D.S.,Robertson, D.,Esler, M.,Straus, S.E.,Eisenhofer, G.(2002).Dysautonomias: clinical disorders of the autonomic nervous system.Ann. Intern. Med.,137,753-763.
29. Guiard, B.P.,Mansari, M.,Merali, Z.,Blier, P.(2008).Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions.Int. J. Neuropsychopharmacol.,11,625-639.
30. Guyenet, P.G.,Haselton, J.R.,Sun, M.K.(1989).Sympathoexcitatory neurons of the rostroventrolateral medulla and the origin of the sympathetic vasomotor tone.Prog. Brain Res.,81,105-116.
31. Hopwood, S.E.,Stamford, J.A.(2001).Noradrenergic modulation of serotonin release in rat dorsal and median raphe nuclei via alpha (1) and alpha (2A) adrenoceptors..Neuropharmacology,41,433-442.
32. Kalsner, S.,Abdali, S.A.(2001).Rate-independent inhibition by norepinephrine of 5-HT release from the somadendritic region of serotonergic neurons.Brain Res. Bull.,55,761-765.
33. Kasparov, S.,Teschemacher, A.G.(2008).Altered central catecholaminergic transmission and cardiovascular disease.Exp. Physiol.,93,725-740.
34. Kerman, I.A.(2008).Organization of brain somatomotor-sympathetic circuits.Exp. Brain Res.,187,1-16.
35. Lapiz, M.D.,Mateo, Y.,Parker, T.,Marsden, C.(2000).Effects of noradrenaline depletion in the brain on response on novelty in isolation-reared rats.Psychopharmacology (Berl),152,312-320.
36. Madden, C.J.,Stocker, S.D.,Sved, A.F.(2006).Attenuation of homeostatic responses to hypotension and glucoprivation after destruction of catecholaminergic rostral ventrolateral medulla neurons.Am. J. Physiol. Regul. Integr. Comp. Physiol.,291,R751-R759.
37. Marien, M.R.,Colpaert, F.C.,Rosenquist, A.C.(2004).Noradrenergic mechanisms in neurodegenerative diseases: a theory.Brain Res. Rev.,45,38-78.
38. Morilak, D.A.,Barrera, G.,Echevarria, D.J.,Garcia, A.S.,Hernandez, A.,Ma, S.,Petre, C.O.(2005).Role of brain norepinephrine in the behavioral response to stress.Prog. Neuropsychopharmacol. Biol. Psychiatry,29,1214-1224.
39. Reneric, J.P.,Bouvard, M.,Stinus, L.(2002).In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed.Eur. Neuropsychopharmacol.,12,159-171.
40. Ressler, K.J.,Nemeroff, C.B.(1999).Role of norepinephrine in the pathophysiology and treatment of mood disorders.Biol. Psychiatry,46,1219-1233.
41. Schatz, I.J.(1984).Orthostatic hypotension. I. Functional and neurogenic causes.Arch. Intern. Med.,144,773-777.
42. Svensson, T.H.,Thoren, P.(1979).Brain noradrenergic neurons in the locus coeruleus: inhibition by blood volume load through vagal afferents.Brain Res.,172,174-178.
43. Tonissaar, M.,Herm, L.,Rinken, A.,Harro, J.(2006).Individual differences in sucrose intake and preference in the rat: circadian variation and association with dopamine D2 receptor function in striatum and nucleus accumbens.Neurosci. Lett.,403,119-124.
44. Vianna, D.M.,Carrive, P.(2010).Cardiovascular and behavioural responses to conditioned fear and restraint are not affected by retrograde lesions of A5 and C1 bulbospinal neurons.Neuroscience,166,1210-1218.
45. Weinshenker, D.,Miller, N.S.,Blizinsky, K.,Laughlin, M.L.,Palmiter, R.D.(2002).Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals.Proc. Natl. Acad. Sci. USA,99,13873-13877.